GlassScriptPhysician profile
Luis Sanchez Russo
NPI 1043661077
$20,668.25
in general payments reported to CMS, 2019-2025
28 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.85 · 2023: $472 · 2024: $5,577 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,650 · Food and Beverage: $5,531 · Consulting Fee: $2,700 · Travel and Lodging: $2,686 · Education: $89.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,650.00 |
| Food and Beverage | $5,531.34 |
| Consulting Fee | $2,700.00 |
| Travel and Lodging | $2,685.63 |
| Education | $89.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $10,868.44 | 2023-2025 | Purified Cortrophin Gel, Iluvien |
| Calliditas Therapeutics US INC. | $4,599.41 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $1,214.46 | 2024-2025 | Filspari |
| Apellis Pharmaceuticals, INC. | $785.66 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $441.17 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $381.89 | 2023-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $367.43 | 2023-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $288.15 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $287.39 | 2024-2025 | Lupkynis |
| Akebia Therapeutics INC | $227.17 | 2024-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $166.13 | 2024-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $139.13 | 2024-2025 | Acthar, Terlivaz |
| Amgen INC. | $129.35 | 2024-2025 | Tavneos, Uplizna |
| Glaxosmithkline, LLC. | $125.80 | 2023-2025 | Benlysta, Jesduvroq |
| Renalytix Ai, INC. | $102.94 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $87.38 | 2023-2024 | Rayaldee |
| Ardelyx, INC. | $65.01 | 2024-2025 | Ibsrela |
| Baxter Healthcare | $64.68 | 2024 | Renal - Pd |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $60.73 | 2025 | Voyxact |
| Vantive US Healthcare LLC | $59.58 | 2025 | Renal - Pd |
| Scpharmaceuticals INC. | $49.48 | 2025 | |
| Novo Nordisk INC | $39.40 | 2024-2025 | Ozempic |
| Merck Sharp & Dohme LLC | $26.87 | 2025 | Prevymis |
| Takeda Pharmaceuticals U.S.A., INC. | $25.23 | 2025 | Gattex |
| Fresenius USA Marketing, INC. | $19.39 | 2025 | Velphoro |
| Lilly USA, LLC | $18.27 | 2024 | Jardiance |
| Corcept Therapeutics | $15.86 | 2025 | Korlym |
| Smith+Nephew, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Sanchez Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.